within Pharmacolibrary.Drugs.ATC.L;

model L02BB05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 2.1333333333333335e-05,
    adminDuration  = 600,
    adminMass      = 240 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.276,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0037500000000000003,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.17,
    k12             = 8.65,
    k21             = 8.65
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02BB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Apalutamide is a non-steroidal androgen receptor inhibitor indicated for the treatment of prostate cancer, specifically non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is approved and used in clinical practice as an oral therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult male patients with prostate cancer after repeated once-daily oral dosing at the recommended clinical dose.</p><h4>References</h4><ol><li><p>Pérez-Ruixo, C, et al., &amp; Ackaert, O (2020). Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects. <i>Clinical pharmacokinetics</i> 59(2) 229–244. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00808-7\">10.1007/s40262-019-00808-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31432469/\">https://pubmed.ncbi.nlm.nih.gov/31432469</a></p></li><li><p>Yu, A, et al., &amp; Hazra, A (2021). Pharmacokinetics and Use-Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration. <i>Clinical pharmacology in drug development</i> 10(11) 1375–1384. DOI:<a href=\"https://doi.org/10.1002/cpdd.1001\">10.1002/cpdd.1001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34273257/\">https://pubmed.ncbi.nlm.nih.gov/34273257</a></p></li><li><p>Gasperoni, L, et al., &amp; De Giorgi, U (2024). New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(6) 491–502. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2353749\">10.1080/17425255.2024.2353749</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38778707/\">https://pubmed.ncbi.nlm.nih.gov/38778707</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02BB05;
